AlphaYou
Overview
Smart money at a glance
Filings to Oct 7, 2026Net buying: insiders sold $286K and bought $12.4M on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$12.1M netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 7- Open
- $14.42
- 52-wk high
- $27.41
- High
- $14.42
- 52-wk low
- $8.72
- Low
- $13.63
- Prev close
- $14.32
- Mkt cap
- $517.8M
- Volume
- 187.0K
- P/S
- 43.6x
- P/B
- 3.3x
- Profit margin
- +0.0%
- Op margin
- -1433.0%
- ROE
- -160.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CBIO filings
Are insiders buying or selling Crescent Biopharma, Inc. (CBIO) stock?
Net buying: insiders sold $286K and bought $12.4M of CBIO stock on the open market in the 90 days to Oct 7, 2026, according to SEC Form 4 filings. $286K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Kiselak, Tomas (Director), who bought $12.4M. The latest filing was on Sep 18, 2026.
Which members of Congress have traded CBIO recently?
None. No member of Congress disclosed a CBIO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CBIO smart-money data?
This summary uses filings available on Oct 7, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- BA
Balyasny
$26.4M
added
- BR
BlackRock
$20.8M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in CBIO right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 2.8% above what analysts expected.
Last report
Jul 30, 2026
Period ending
Jun 30, 2026
Adjusted EPS
-$0.64 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | -$0.62 / -$0.64Yahoo Finance | +2.83% beat | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 29, 2026 | -$0.70 / -$0.79Yahoo Finance | +11.02% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 26, 2026 | -$4.92 / -$2.82Yahoo Finance | -74.47% miss | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | -$1.37 / -$1.39Yahoo Finance | +1.26% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | -$3.72 / -$3.68Alpha Vantage | -1.09% miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 14, 2025 | -$18.39 / -$3.64Alpha Vantage | -$14.75 miss | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 13, 2025 | -$0.08 / -$0.09Alpha Vantage | +$0.01 beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 13, 2024 | -$15.24 / -$0.11Alpha Vantage | -$15.13 miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 5, 2026, in 29 days
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Market cap
- $518M
Valuation
- P/S43.58
- P/B3.31
Quality
- Operating margin-1433.0%
- ROE-160.7%
- ROA-69.2%
Growth
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace